Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report.
10.3802/jgo.2010.21.4.269
- Author:
Ye Won CHUNG
1
;
Hyo Sook BAE
;
Song I HAN
;
Jae Yoon SONG
;
In Sun KIM
;
Jae Seong KANG
Author Information
1. Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea. kumcjskang@hanmail.net
- Publication Type:Case Report
- Keywords:
Toremifene;
Tamoxifen;
Mullerian adenosarcoma;
Mullerian adenofibroma;
Breast cancer
- MeSH:
Adenofibroma;
Adenosarcoma;
Breast;
Breast Neoplasms;
Endometrial Neoplasms;
Female;
Humans;
Risk Assessment;
Tamoxifen;
Toremifene
- From:Journal of Gynecologic Oncology
2010;21(4):269-272
- CountryRepublic of Korea
- Language:English
-
Abstract:
Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.
